Ranbaxy generics, gastrointestinal, infectious news

Ranbaxy filed a suit in the U.S. District Court for the District of Columbia alleging that FDA improperly concluded that the company forfeited its 180-day exclusivity for a generic version of Valcyte valganciclovir from Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland). Under

Read the full 403 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE